Scenic Biotech

Scenic Biotech is a biopharmaceutical company based in Amsterdam, Netherlands, founded in 2017.

The company focuses on developing disease-modifying therapies for neurological and metabolic diseases, including rare genetic disorders and cancer. Scenic Biotech operates as a spin-out from the Netherlands Cancer Institute and Oxford University and is privately held with a team of around 42 employees. The company utilizes its proprietary discovery platform, Cell-SeqTM, which employs human haploid cells to identify genetic modifiers that can suppress the effects of disease-causing mutations. Scenic Biotech's pipeline includes first-in-class small molecule programs targeting conditions such as lysosomal storage disorders, neurodegeneration, and cancer through immuno-oncology. The company collaborates with major biopharma partners to advance its research and development efforts, aiming to provide innovative therapies for patients with rare genetic disorders and other serious health conditions.